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Smail Hadj-Rabia, MD-PhD9, Julie Harris, RN1, Georgios Kounidas, MPhil1, Parag Kumar, PharmD8,
Marjorie J. Lindhurst, PhD2, Romaric Loffroy, MD-PhD10, Ludovic Martin, MD-PhD11,
Alice Phan, MD-PhD12, Kristina I. Rother, MD6, Brigitte C. Widemann, MD13, Pamela L. Wolters, PhD13,
Christine Coubes, MD14, Lucile Pinson, MD14, Marjolaine Willems, MD-PhD14,
Catherine Vincent-Delorme, MD15 PROMISE Working Group#, Pierre Vabres, MD-PhD3,
Robert K. Semple, MBChir PhD1,16 and Leslie G. Biesecker, MD2
Purpose: PIK3CA-related overgrowth spectrum (PROS) encom-
passes a range of debilitating conditions defined by asymmetric
overgrowth caused by mosaic activating PIK3CA variants. PIK3CA
encodes the p110α catalytic subunit of phosphatidylinositol-3-
kinase (PI3K), a critical transducer of growth factor signaling. As
mTOR mediates the growth-promoting actions of PI3K, we
hypothesized that the mTOR inhibitor sirolimus would slow
pathological overgrowth.
Methods: Thirty-nine participants with PROS and progressive
overgrowth were enrolled into open-label studies across three
centers, and results were pooled. For the primary outcome, tissue
volumes at affected and unaffected sites were measured by dual
energy X-ray absorptiometry during 26 weeks of untreated run-in
and 26 weeks of sirolimus therapy.
Results: Thirty participants completed the study. Sirolimus led to a
change in mean percentage total tissue volume of –7.2% (SD 16.0,
p= 0.04) at affected sites, but not at unaffected sites (+1.7%, SD
11.5, p= 0.48) (n= 23 evaluable). Twenty-eight of 39 (72%)
participants had ≥1 adverse event related to sirolimus of which
37% were grade 3 or 4 in severity and 7/39 (18%) participants were
withdrawn consequently.
Conclusion: This study suggests that low-dose sirolimus can
modestly reduce overgrowth, but cautions that the side-effect
profile is significant, mandating individualized risk–benefit evalua-
tions for sirolimus treatment in PROS.
Genetics in Medicine (2018) https://doi.org/10.1038/s41436-018-
0297-9
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INTRODUCTION
PIK3CA-related overgrowth spectrum (PROS) designates a
heterogeneous group of rare, asymmetric overgrowth dis-
orders caused by postzygotic variants in the gene PIK3CA.1
PIK3CA encodes the p110α catalytic subunit of phosphoino-
sitide 3-kinase (PI3K), which transduces activation of tyrosine
kinase growth factor and hormone receptors into activation of
AKT and mTOR signaling2 to promote tissue growth.
PIK3CA variants in PROS cause physiologically inappropriate
activation of AKT and mTOR, and variable, asymmetric
overgrowth, consistent with causation by an early
developmental stochastic pathogenic variant. Overgrowth
includes adipose tissue, muscle, skin, bone, blood or lymph
vessels, or neural tissue, among others.3–6 Adipose and
vascular components are particularly striking, reflecting the
inherent plasticity and postnatal growth potential of these
tissues. Complications of PROS depend on the anatomical site
and extent of overgrowth, but may include functional
impairment (e.g., of walking or swallowing), pain, recurrent
superficial infections, thromboembolism, and/or hemorrhage,
all of which may be debilitating, and cause early mortality.
Current treatment is inadequate, relying on debulking
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surgery, amputation, and/or endovascular occlusive proce-
dures. Regrowth following surgery occurs frequently and
repeated surgery is common.7
Some genotype–phenotype correlation in PROS has been
suggested,8,9 however the dominant determinant of pheno-
type is the timing and location of the pathogenic variant . This
causes a high degree of interindividual phenotypic hetero-
geneity in PROS. Compounding this, growth trajectories vary
greatly for unknown reasons, with some exhibiting excess
growth limited to childhood, while others have progressive
soft tissue overgrowth during adult life. Finally, overgrown
tissue usually lacks the clear anatomical demarcation
characteristic of neoplasia on imaging. Collectively these
considerations complicate the design of quantitative end-
points for therapeutic studies.
Allosteric mTOR inhibitors such as sirolimus are approved
for posttransplant immunosuppression. They can also slow
the growth of cancers bearing PIK3CA variants.10 Sirolimus
potently attenuates pathological AKT signaling and reduces
cell proliferation in dermal fibroblasts derived from people
with PROS,11,12 which suggests that it could be an effective
treatment of PROS. Anecdotal reports of sirolimus therapy in
PROS have suggested efficacy,13,14 while other studies have
reported clinical improvement in patients with vascular
overgrowth caused by TIE2 variants15 or of unknown
cause.16,17 Further, unpublished patient and clinician reports
suggest wider off-label use of sirolimus in PROS. To assess the
potential efficacy of sirolimus in PROS further, and to address
the challenges of study design, we undertook a study of low-
dose sirolimus in patients with molecularly proven PROS,
assessing quantitative disease endpoints. The study was
conducted across three centers using a common protocol.
MATERIALS AND METHODS
This pilot study was performed in accordance with the
Declaration of Helsinki and Good Clinical Practice guidelines
or the US human subject research regulations (US Code of
regulations 45CFR46). The study protocol was approved by
ethics review boards of each study site. Regulatory approval
from the Medicines and Healthcare Products Regulatory
Agency (MHRA) was obtained in the United Kingdom, and
Agence Nationale de Sécurité du Médicament et des Produits
de Santé (ANSM) in France. Written informed consent and/
or parental consent and where possible assent for the
participation of children was obtained for all participants.
Study Registration: France (NCT02443818), United Kingdom
(EudraCT: 2014-000484-41), United States (NCT02428296).
Study overview and design
We selected a nonrandomized, open-label design with a 26-
week observational run-in period to measure growth (Fig. 1a).
The study was conducted at Cambridge University Hospitals
NHS Trust (United Kingdom), CHU Dijon-Bourgogne
(France), and the National Human Genome Research
Institute (United States) (Supplemental Table S1). Intraparti-
cipant comparisons between affected and matched unaffected
contralateral tissue were made where possible. A placebo was
excluded pragmatically due to growing awareness of the
availability of sirolimus and its increasing off-license use in
PROS, potentially compromising recruitment within this
orphan disease population. Participants were assessed for
sirolimus efficacy at week 0 (before the run-in phase), week 26
(after the run-in phase and before treatment), and at week 52
(after 26 weeks of treatment).
Inclusion/exclusion and withdrawal criteria
Eligible participants were aged from 3 to 65 years, inclusive.
All had a diagnosis of PIK3CA-related overgrowth spectrum
(PROS)9,18 with progressive overgrowth (determined by self-
report or serial measurements) and a mosaic PIK3CA variant
identified by methodology described previously.5,9,18 (Table 1).
The main exclusion criteria were use of sirolimus in the prior
4 weeks; active skin infections; major surgery in the prior
12 weeks; pregnancy and lactation; live vaccines in the 4 weeks
prior to, during, and 6 weeks after dosing; insufficient renal,
hepatic, or bone marrow function; or prior/intercurrent HIV,
hepatitis B/C, or tuberculosis infection. In the United
Kingdom and France, participants with a blood neutrophil
count of <1.0 × 109/l were excluded; in the United States,
participants with a count of <1.5 × 109/l, or <1.0 × 109/l and a
diagnosis of benign ethnic neutropenia were excluded.
Participants were withdrawn if they or their parents
requested, or if adverse events (AEs) of grade ≥3 occurred
including neutropenia (<1.0 × 109/l in France and the United
Kingdom, <0.5 × 109/l in the United States); proteinuria (e.g.,
3+ on qualitative testing); liver dysfunction (alanine transa-
minase [ALT] >3 times the upper limit of normal); renal
dysfunction (glomerular filtration rate [GFR] <70 mls/min/
1.73 m2); pneumonitis or decline in respiratory reserve;
severe, recurrent infections or septicemia; QTc prolongation;
or other side effects at the discretion of the lead investigator at
each site.
Dosing regimen
Pharmacokinetic data for sirolimus for children and adults
with renal transplants informed dosing algorithms.19 A target
sirolimus plasma concentration of 2–6 ng/ml was selected
based on in vitro preclinical studies20 off-label clinical
experience,13 and with the aim of minimizing AEs. Given
the known immunosuppressive effects of high-dose sirolimus,
the lack of evidence that these doses are more efficacious in
PROS, and the likely need for lifelong therapy we titrated
dosing to achieve this target concentration. Steady state was
defined as two consecutive concentrations within 10% of each
other. Dosing and sirolimus monitoring regimens between the
UK, France, and US sites are outlined in Supplemental
Table S5. Treatment was paused during intercurrent infection,
surgical intervention, or other AE when necessary.
Biochemical evaluation
Laboratory assessments included blood cell counts, indices of
renal function and liver function, fasting blood glucose and
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lipid profiles, and urinalysis including protein semiquantifica-
tion. Sirolimus assays were performed in accredited clinical
diagnostic laboratories.
Quantification of overgrowth
Affected sites were defined by clinical observation. Unaffected
sites showed no overgrowth, nor evidence of skin or vascular
abnormalities. Unaffected sites compared with affected sites
were (in order of preference) the contralateral limb/truncal
region, a limb or trunk on the same side, or any other site
without clear involvement. Those with generalized, but
asymmetric overgrowth were deemed to have no unaffected
site.
Dual energy X-ray absorptiometry (DXA) scans were
performed using the same orientation and iDXA GE Lunar
scanner for each participant at 0, 26, and 52-week time points.
DXA imaging provides reproducible measurement of regional
and whole body composition (bone, fat, and lean mass),21
though it cannot assess vascular or lymphatic malformations.
We used DXA to evaluate the primary outcome measure in
view of its wide applicability, its acceptability to children, and
its capacity to generate concurrent estimates of unaffected and
affected tissue sites. For adults too large to scan completely
with one scan (n= 3), a second scan was performed to give
full body coverage. Soft tissue volumes were obtained for total
body and various body segments (left leg, right leg, right
trunk, left trunk, right arm, left arm, and head) by converting
masses to volumes assuming fat density of 0.9 g/ml and lean
mass density of 1.1 g/ml.22 Total tissue volume included lean
and fat volume, but not bone. Results were generated using
the same, standardized iDXA GE Lunar software at each
center.
T1-weighted magnetic resonance imaging (MRI) scans
without contrast were also acquired in a subset of participants
at 0, 26, and 52 weeks using the same scanner at each site (GE
GEMR450 wide in the United Kingdom, IRM Siemens
Magnetom Aera 1.5T in France, and 3T MRI scanner [Trio,
Siemens Medical Solutions] in the United States). Scanning
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Run-in
Eligibility
Allocation
Intervention
Follow-up
Analysis
Bloods
final follow-up
Bloods
sirolimus follow-up
Screened
N=41
Allocated to
sirolimus
N=39
Received
sirolimus
N=39
Completed
follow-up
N=30
Analyzed: Primary outcome N=23
Secondary outcomes N=30
Safety and tolerability N=39
Withdrawn/
discontinued
N=9
Sirolimus
0 26 27 28 30 38 52 54 Weeks
Fig. 1 CONSORT flow-chart and schematic of nonrandomized open-label pilot study. a Schematic of number of participants assessed for eligibility
and excluded or allocated to the study, treated, followed, and analyzed. Of the 39 subjects enrolled, 30 completed 26 weeks of sirolimus therapy, and 23/30
had anatomy that permitted analysis of the primary outcome measure. Safety and tolerability were evaluated in all treated participants. b Overview of study
design including schedule of procedures. AE/SAEs adverse events/serious adverse events, CXR chest X-ray, DXA/MRI dual energy X-ray absorptiometry/
magnetic resonance imaging, QOL quality of life.
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covered bony anatomical landmarks at proximal and distal
ends of the target area, and an oblique scan plane of 5 mm
thickness with up to 100 slices was used. All scans were
blinded prior to analysis. For volume calculation, IDEAL fat
(Dixon sequence) images were visualized using volumetric
software (SliceOmatic, TomoVision, Magog, Canada). Mor-
phology segmentation was performed through computation
of watershed gradients. Tissues (fat, muscle, bone, and blood
vessel) were manually defined and software was used to
generate a surrogate of tissue volume using five slices, with
manual adjustments where required.
Evaluation of vascular lesions
Clinical photography was performed in participants with
visible vascular lesions before and after sirolimus treatment
using the same camera in the same room with consistent
lighting and color balance. Unblinded assessment by a study
investigator was undertaken using the following scoring
system: –1=worsening; 0= no change; 1= partial resolu-
tion; 2= complete resolution. Vascular lesions were scored by
hue, with annotation regarding the presence of lymphatic
blebs.
Quality of life assessment
Validated quality of life (QOL) questionnaires were adminis-
tered before and after treatment (WHOQOL-BREF ques-
tionnaire for adults,23 and age-appropriate PedsQL
questionnaires for children and parents24,25). The
WHOQOL-BREF assesses four domains (physical, psycholo-
gical, social, environmental).26,27 The PedsQL Generic Core
Table 1 Baseline characteristics of enrolled participants
UK France US Combined
N= 11 N= 15 N= 13 N= 39
Mean age, years (range) 19.8 (5–44) 16.4 (3–39) 13.6 (3–48) 16.6 (3–48)
Gender F:M 4:7 7:8 6:7 17:22
PIK3CA variant
c.3132T>A p.(Asn1044Lys) 1/13 (8%) 1/39 (3%)
c.31327A>G p.(Met1043Val) 1/15 (7%) 1/39 (3%)
c.31340A>G p.(His1047Arg) 4/11 (36%) 3/15 (20%) 4/13 (31%) 11/39 (28%)
c.3140A>T p.(His1047Leu) 2/15 (13%) 1/13 (8%) 3/39 (8%)
c.3139C>T p.(His1047Tyr) 1/13 (8%) 1/39 (3%)
c.3073A>G p.(Thr1025Ala) 1/11 (9%) 1/39 (3%)
c.1637A>G p.(Gly546Arg) 1/15 (7%) 1/39 (3%)
c.1636C>A p.(Gly546Lys) 1/15 (7%) 1/39 (3%)
c.1633G>A p.(Glu545Lys) 2/15 (13%) 2/39 (5%)
c.1624G>A p.(Glu542Lys) 1/11 (9%) 3/15 (13%) 2/13 (15%) 6/39 (15%)
c.1357G>A p.(Glu453Lys) 2/13 (15%) 2/39 (5%)
c.1252G>A p.(Glu418Lys) 1/11 (9%) 1/39 (3%)
c.1132T>C p.(Cys378Arg) 1/13 (8%) 1/39 (3%)
c.1049A>G p.(Asp350Gly) 1/11 (9%) 1/39 (3%)
c.1038_1040dup p.(Val346_Asn347insLys) 1/11 (9%) 1/39 (3%)
c.1035T>A p.(Asn345Lys) 1/15 (7%) 1/39 (3%)
c.328_330delGAA p.(Glu110del) 1/11 (9%) 1/15 (7%) 1/13 (8%) 3/39 (8%)
c.241G>A p.(Glu81Lys) 1/11 (9%) 1/39 (3%)
Mean start BMI (adults ≥16 years) kg/m2 32.6 (24.9–41.8) 24.1 (20.2–25.6) 38.8 (27.0–49.4) 31.8 (20.2–49.4)
Mean start BSA m2 (children <16 years) 1.09 (0.63–1.51) 1.13 (0.61–1.44) 0.97 (0.62–1.36) 1.06 (0.61–1.51)
Site of overgrowth
Generalized 3/11 (27%) 2/15 (13%) 3/13 (23%) 8/39 (21%)
Facial 1/11 (9%) 0 3/13 (23%) 4/39 (10%)
Upper limb only 1/11 (9%) 0 0 1/39 (3%)
Lower limb only 3/11 (27%) 7/15 (47%) 4/13 (31%) 14/39 (36%)
Upper and lower limbs 0 1/15 (7%) 2/13 (15%) 3/39 (8%)
Thoracic region only 0 0 0 0
Thoracic region and limbs 2/11 (9%) 1/15 (7%) 0 3/39 (8%)
Truncal region only 0 0 0
Truncal region and limbs/thoracic region 1/11 (9%) 3/15 (20%) 7/13 (54%) 11/39 (28%)
Vascular/venous malformations 2/11 (18%) 11/15 (73%) 10/13 (77%) 23/39 (59%)
BMI body mass index, BSA Body Surface Area
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Scales assess four domains (physical, emotional, social, and
school) and two composite scores (physical, psychosocial),
which were transformed to a 0–100 scale (25).
Outcome measures
The primary outcome measure was percentage change in
volume of measured affected and unaffected areas over treated
and untreated periods. Fat, lean, and total (fat plus lean) tissue
volumes were determined. Both DXA and volumetric MRI
scanning were undertaken where possible and anatomically
appropriate. Prior to analysis, DXA was selected for the
primary outcome measure as DXA results were available in all
participants whereas MRI was only performed in a subset.
Secondary outcome measures were steady-state sirolimus
plasma concentration, mean sirolimus doses to achieve the
target plasma concentration, and additional measures of
efficacy including hospitalizations, surgical interventions, and
QOL scores before and after treatment.
Statistical analyses
Intention-to-treat analyses were based on all enrolled
participants. As-treated analyses were restricted to those
who completed the study. Absolute volumes of affected and
unaffected tissue at week 0 (designated X), week 26
(designated Y), and week 52 (designated Z), were compared.
Tissue volume changes (week 0–26 and week 26–52) were
designated “DELTA,” and the percent change “% Change.”
Percent change for the untreated period was [100(Y–X/X)],
and for the treated period [100(Z–Y/Y)]. Paired comparisons
of mean volumes and mean changes in volumes during
untreated ad treated periods were performed using single-
sample, paired Student’s t test in SAS version 9.4, with
confirmation of equal variances. A post hoc subanalysis was
performed to examine the difference % change in tissue at
affected and unaffected sites during the treatment phase in
comparison with the run-in phase according to age, genotype,
and phenotypic characteristics. Linear regression and analysis
of variance (ANOVA) analyses were performed to evaluate
statistical significance. Additional statistical analyses of
normally distributed data of equal variance were performed
using single-sample Student’s paired t tests and chi-squared
analyses for discontinuous data.
Safety analysis
Safety endpoints were adverse events (AEs) identified by
laboratory testing, clinical examination, or self-report. Severity
was graded with the Common Terminology Criteria for
Adverse Events (CTCAE) (version 4.0). AEs were coded by
the current version of the Medical Dictionary for Regulatory
Activities (MedDRA), and the type, incidence, severity, and
relationship to sirolimus were summarized by MedDRA
System Organ Class and Preferred Term. Serious adverse
events (SAEs) were defined as those that led to death, were life-
threatening, necessitated hospital admission or prolongation of
an admission, or that resulted in persistent or severe disability
or incapacity, congenital anomalies, or any other medically
important events. All AEs and SAEs possibly, probably, or
definitely related to sirolimus were reviewed by an interna-
tional committee composed of members of the study teams
from the United Kingdom, France, and the United States.
RESULTS
Study participants and disposition
Forty-one participants were screened and 39 enrolled,
including 22 children (<16 years old) and 17 adults (≥16
years old) (Fig. 1b). The mean age was 16.6 years (SD 11.0,
range 3–48); 44% were female and 56% male. Clinical
characteristics of these participants are detailed in Supple-
mentary Table S2, and representative images illustrating the
overgrowth heterogeneity are shown in Fig. 2. Thirty
participants completed 26 weeks of dosing, 2 discontinued
the study after 23 weeks of dosing due to a temporary pause in
dosing at one of the sites, and 7 were withdrawn due to AEs
(Fig. 1b) (Supplementary Table S3). Of the 30 who completed
26 weeks dosing, 97% received >80% of their daily doses.
Sirolimus plasma levels and dosing
The mean plasma sirolimus level recorded across the study in
both adults and children was 3.4 ng/ml (95% confidence
interval [CI] 3.1, 3.7), and the median level 3.3 ng/ml (25th/
75th centiles 2.3, 4.2). The mean total daily sirolimus dose in
adults was 1.2 mg once daily in capsules (95% CI 1.1, 1.3), and
for children was 0.58 mg twice daily in oral solution (95% CI
0.50, 0.65).
Efficacy-based outcome measures
Volumes of fat and lean components of affected and (where
possible) unaffected soft tissue body regions were measured
using DXA at 0, 26, and 52 weeks (Fig. 3a). The anatomy of
23 participants permitted comparison of affected versus
unaffected. Absolute tissue volumes were greater and more
variable at affected versus unaffected sites as expected; at week
0 median total tissue volume at affected sites was 10,132 ml
(interquartile range [IQR]: 4980, 17,055) and 3013 ml (IQR:
1465, 8599) at unaffected sites. In the untreated run-in period,
the mean increase in total tissue volume at affected sites was
+7.9% (SD 12.8) versus +4.8% (SD 9.7) at unaffected sites,
(p= 0.19; SD 10.9) (Fig. 3b).
For the primary outcome measure, a significant reduction
of –7.2% (SD 16.0; p= 0.04) was observed in the volume
change of affected tissues during sirolimus treatment. In
contrast, there was no significant increase for unaffected
tissue (+1.7%, SD 11.5; p= 0.48). A significant reduction in
lean tissue (muscle, connective tissue, and vasculature) of
–6.3% (SD 13.3; p= 0.03) and a trend toward reduction of fat
of –9.8% (SD 24.4; p= 0.07) was observed at affected but not
unaffected sites during treatment (Supplementary Table S4).
Viewing individual data points on scatter plots comparing
volume changes in treated and untreated phases reinforces
this conclusion (Supplementary Figure S1).
A post hoc subanalysis was performed to assess differences
in response by age, clinical phenotype (qualitatively
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predominant adipose overgrowth, vascular overgrowth, or
muscular/bony overgrowth), genotype, or overgrowth rate
during the run-in period (Supplementary Figure S2). A
significant correlation between the magnitude of treatment
effect (difference between tissue volume changes in treatment
and run-in periods) and of progressive overgrowth during the
run-in period was seen (Fig. 3c). In addition, there was a
trend toward greater tissue volume reduction in participants
with predominant adipose overgrowth (–8.9% [SD 14.9], n=
17/23) than in participants without predominant adipose
overgrowth (–2.4% [SD 19.4], n= 6/23, p= 0.14). There were
no apparent differences with respect to age, genotype, or the
presence/absence of vascular/venous malformations.
Serial MRI analyses of tissue volume were available for only
10/20 participants due to the site of overgrowth not being
amenable to MRI scanning, or due to insufficient quality of
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acquired images for analysis. Technical challenges included
variation in participant position and movement, varying slice
thickness between scans, and anatomical factors such as fat
investiture into muscles, preventing clear definition of tissue
planes (Supplementary Figure S3). Only six of ten MRI series
that were eligible for analysis included both affected and
unaffected sites. No statistically significant differences in
tissue volume changes between the treatment phase and run-
in phase were seen for either affected sites (–3.7% [SD 12.3];
p= 0.37) or unaffected sites (0% [SD 16.7]; p= 0.99).
Secondary outcome measures
No differences were detected in QOL scores before and after
sirolimus treatment (Supplementary Table S5) among adults
or children. During run-in, five hospitalizations in five
participants and two surgical interventions in two participants
were recorded. In the treatment phase 15 hospitalizations in 9
participants and no surgical interventions arose. This
difference was not significant (p= 0.24). Clinical photographs
were evaluated for eight participants with superficial capillary
or venous malformations and none changed during treat-
ment. Five participants had lymphatic malformations and of
these, two showed evidence of improvement with decreased
superficial lymphangiectasis (Supplementary Figure S4), with
three unchanged.
Safety and tolerability
Twenty-eight of 39 participants (72%) had at least one AE
deemed possibly, probably, or definitely related to sirolimus
(Table 2). Twenty-one serious AEs (SAEs) (Supplementary
Table S6) occurred among 12 participants during either run-
in or treatment periods, and 7 had AEs leading to sirolimus
discontinuation. The most common class of AE was infection
(16/39 [41%] participants), followed by blood or lymphatic
disorders (8/39 [21%]) (Supplementary Table S7). Clinically
important AEs included grade 4 neutropenia (neutrophil
count 0.02 × 109/L), interstitial pneumonitis, and sirolimus
hypersensitivity syndrome. This last SAE presented with
prolonged fever and resulted in hospitalization for more than
6 weeks. Sirolimus was withdrawn in all three participants, all
of whom subsequently made full recoveries. There were no
significant changes in laboratory assessments including lipid
profiles and fasting glucose concentrations in the treatment
period.
DISCUSSION
In this study 26 weeks of low-dose sirolimus therapy was
associated with a small, but significant reduction in tissue
growth at overgrown sites in participants with PROS. There
was no measured effect on QOL or the overall extent of
PROS-related skin lesions. These findings bolster the notion
that sirolimus may be beneficial in PROS. One aim of this
study was to inform selection of endpoints, and the powering
and design of such trials.
Overgrowth in PROS comprises admixture of adipose
tissue, vascular tissue, and bone. We anticipated that adipose
and vascular tissues would be the most likely to respond to
short-term treatment, given their natural capacity for rapid
growth in the face of positive energy balance or injury.
Furthermore, as these tissues can also regress physiologically,
and as PIK3CA is involved in both cell proliferation and
suppression of apoptosis, shrinkage of previously overgrown
tissue rather than just deceleration of pathological overgrowth
seemed a conceivable outcome of therapy. Using DXA body
composition analysis we did not document evidence of
significant and selective regression of affected tissue; however,
overgrowth during run-in was associated with greater
reduction in tissue volume during treatment. We also set
out to use volumetric MRI to quantify adipose tissue volumes;
however, technical and analytic challenges and inconsistency
in serial imaging compromised this. MRI may nevertheless
still be useful with more rigorous control of positioning and
slice thickness.
This study had several limitations. Despite genetic homo-
geneity, phenotypic heterogeneity among participants was
considerable. Post hoc subanalyses based on phenotype were
inconclusive due to small sample size. Formally establishing
whether our findings are generalizable to all PROS compo-
nents, including the minor end of the phenotypic spectrum,
will require availability of large PROS cohorts in future
studies. The high frequency of study visits during treatment
and the nonrandomized, open-label design may have led to
Fig. 2 Clinical heterogeneity of study participants with PIK3CA-related overgrowth spectrum. a 15-year-old girl with fibroadipose hyperplasia of
left arm; unaffected right arm (patient 1). b 39-year-old man with fibroadipose and bony hyperplasia of left lower leg, foot s/p multiple amputations, and
lipectomies; unaffected right leg, foot (patient 17). c 48-year-old woman with tongue fibromas, fibroadipose hyperplasia masses of trunk, back, paraspinal s/
p (status post) excision, and scoliosis s/p surgical bracing (patient 30). d 5-year-old boy with fibroadipose hyperplasia of the left leg, buttock visualized on
magnetic resonance image (MRI) scan (patient 4). e 17-year-old boy with right fibroadipose hemihyperplasia (patient 2). f 19-year-old woman with right
fibroadipose hemihyperplasia and capillary malformation, MCAP (Megalencephaly-capillary malformation syndrome) phenotype (patient 3). g 6-year-old girl
with vascular malformations/overgrowth of left leg, foot; unaffected right leg, foot (patient 19). h 26-year-old man with vascular malformations/overgrowth
of right leg; unaffected left leg (patient 12). i 23-year-old man with vascular malformations of the left arm and hand (patient 13). j 3-year-old boy with
fibroadipose hyperplasia of the right arm, hand, fingers, and trunk and left partial chest/axilla (patient 16). k 44-year-old man with fibroadipose hyperplasia
and vascular malformations of his back and bilateral legs (patient 10). l 8-year-old girl with fibroadipose hyperplasia masses of her trunk, back, paraspinal s/p
excision, muscular hyperplasia of her legs and feet (left > right), regional lipohypoplasia of her bilateral arms (patient 27). m 6-year-old boy with facial
infiltrating lipomatosis affecting left cheek visualized on MRI scan (patient 9). n 31-year-old man with vascular malformations and fibroadipose hyperplasia
of the lower trunk, leg (patient 5). o 13-year-old boy with epidermal nevus of right face, neck; right facial, tongue, trunk, bilateral legs, feet (right > left)
fibroadipose hyperplasia s/p multiple amputations/debulking surgeries of feet and toes; lymphovascular malformations of bilateral arms (right > left), trunk
(patient 29). Written informed consent was obtained for use of all identifiable images.
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overestimation of AEs. Furthermore, the time taken for
sirolimus plasma concentrations to reach steady state and
interruption of treatment due to intercurrent AEs in some
patients will have reduced drug exposure and thus any
treatment effect. The QOL assessment was limited by small
sample sizes, and use of a generic assessment tool that omitted
pain and functional impairment scoring. Additional tools
exist, but none are specifically tailored to the PROS spectrum.
Finally, participants who had generalized but asymmetric
overgrowth were not included in the primary outcome
analysis as an unaffected site could not be identified. In other
patients, the “affected” and “unaffected” body regions we
studied were defined based on clinical and radiographic
appearances. However, the presence of variant-positive cells
in apparently unaffected sites cannot be excluded, and thus
growth at these sites could be at least partly pathologic.
Our findings suggest that, in the 26-week period assessed,
sirolimus exerted its greatest effect on actively growing tissue,
rather than inducing regression of prior overgrowth. Siroli-
mus did not significantly reduce tissue growth in unaffected
areas, suggesting that sirolimus does not inhibit normal
cellular growth at low doses. Subanalyses suggested a greater
response in participants with predominantly adipose over-
growth; however, only the effect on lean tissue volume,
assessed by DXA, reached significance. We cannot rule out
greater effects of higher doses of sirolimus or longer durations
of therapy; however, the effect size we observed will be of
value in powering future studies.
Table 2 Overview of adverse events (AEs) and serious
adverse events (SAEs)
Intention-to-treat
population (n=39)
Total number of AEs recorded 103 AEs in 31/39 (79%)
participants
54/103 AEs (52%)
unrelated to sirolimus
At least one sirolimus-related AE (all grades) 28/39 (72%)
At least one event of ≥ grade 3 severity 13/39 (33%)
Death (grade 5) 0 (0%)
At least one SAE 11/39 (28%)
At least one SAE and ≥ grade 3 severity 10/39 (26%)
At least one event leading to permanent
discontinuation of sirolimus
7/39 (18%)
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Fig. 3 Dual energy X-ray absorptiometry (DXA)-estimated changes in tissue volume during study period. a Change in absolute volumes in ml at
affected and unaffected sites at the beginning of the run-in period (week 0), after the 26-week run-in period (week 26), and after the 26-week sirolimus
treatment period (week 52). Note major differences in the magnitude and variability of volume measurements between affected and unaffected sites.
b Change in percent tissue volume at affected and unaffected sites during the run-in period at week 26 and during the sirolimus treatment phase at week
52. Individual values plotted, bars denote mean values and error bars standard deviation. c Post hoc subanalysis of progressive growth during the run-in
period. Linear regression analysis of % volume change during run-in period, i.e., whether or not subjects had progressive overgrowth versus difference in %
volume change between the run-in and treatment phase at affected sites. The result was significant implying the largest effect sizes were obtained in
subjects with progressive overgrowth during the run-in period.
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A recent study by Adams et al.17 assessed a higher dose of
sirolimus in a heterogeneous cohort with primarily vascular
malformations. No genetic characterization was reported, but
some were likely to have PROS based on clinical phenotypes.
In that study, disease response (complete or partial) was
defined with respect to radiologic imaging or QOL measures.
No participant had complete response, and 87% had partial
response, in some cases due only to changes in QOL
measures. That study had limitations of likely heterogeneous
etiology, no control or run-in period was used, affected and
unaffected sites were not compared, and various imaging
modalities were employed.
Medical therapy for PROS is likely to be suppressive rather
than curative, and may be indefinite from childhood. Mindful
of this, and of evidence that low concentrations of mTOR
inhibitors are sufficient ex vivo to suppress basal hyperactiva-
tion of PI3K in cells from people with PROS,12,20 we used
low-dose sirolimus to attempt to reduce the AE rate reported
with higher doses. This yielded plasma concentrations below
the immunosuppressive range used after organ transplanta-
tion. Nevertheless, a considerable number of AEs, several
severe, were recorded, leading to 7 discontinuations of
treatment, although 11/39 (28%) participants had no reported
AEs. In comparison with Adams et al.17 we observed higher
rates of discontinuation and infection-related AEs (41% in
this study versus 15% [ref. 17] for CTCAE grade 2 or higher),
but a lower incidence of hematological AEs (5% versus 27%
[ref. 17] for CTCAE grade 3 or higher). In contrast, an AE
profile that similar to ours was reported in a study of
everolimus in tuberous sclerosis.28 There, 11/28 (39%)
participants had a ≥ grade 3 event (versus 13/39 [33%] in
our study) and the most frequent events were stomatitis 22/28
(79%), upper respiratory tract infection 22/28 (79%), and
sinusitis 11/28 (39%). Discontinuation rates were only 1/28
(3.5%) in the first 6 months in the tuberous sclerosis trial. It is
unclear whether some of the reported differences relate to the
biology of PROS, to the heterogeneity of the participants in
the prior studies, or whether they reflect a greater risk of
infection with sirolimus therapy in PROS. Immunodeficiency
is seen in several germline disorders featuring activated PI3K
signaling, but in many patients with PROS the variant allele
fraction in blood is undetectable or extremely low. We
conclude that use of low-dose sirolimus in this study did not
demonstrably decrease AE rates seen with higher-dose
therapy.29
In summary, sirolimus has potential benefit for patients
with PROS, especially where progressive adipose tissue
overgrowth predominates. Randomized controlled trials with
designs optimized for rare disease research are required to
confirm this, and to establish the optimal therapeutic window,
especially given our observed high rate of discontinuations
despite the use of low-dose treatment. Based upon these
results, sirolimus use in PROS should be evaluated on a case-
by-case basis. Our study holds lessons for design of future
trials, whether of mTOR inhibitors, or of trial agents targeting
the PIK3CA gene product directly. The importance of
objectively establishing the efficacy of sirolimus for PROS
assumed new urgency while this study was in review, with the
reporting of an uncontrolled, unregistered case series of
patients with PROS treated with an experimental PIK3CA
inhibitor on a compassionate basis.30 These anecdotal data
suggested clinical efficacy without significant side effects;
however, neither safety nor efficacy endpoints were pre-
specified. Testing of such agents in formal trials, perhaps
against sirolimus, should be undertaken to permit objective,
quantitative assessment of outcomes and AEs before unregu-
lated use becomes widespread.
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